Adagio Medical 2024 Q4 Earnings Misses Targets as Net Loss Widens 565.5%
Generated by AI AgentAinvest Earnings Report Digest
Friday, May 16, 2025 10:00 am ET2min read
ADGM--
Adagio Medical (ADGM) reported its fiscal 2024 Q4 earnings on May 15th, 2025. The company missed expectations as its net loss widened significantly, despite a substantial increase in revenue. Guidance remains in line with previous forecasts, indicating continued momentum in clinical trials and product development. Investors are advised to consider these factors, alongside the company’s optimistic outlook and strategic initiatives, when evaluating Adagio Medical's future performance.
Revenue
The total revenue of Adagio MedicalADGM-- increased by 75.6% to $137,000 in 2024 Q4, up from $78,000 in 2023 Q4.
Earnings/Net Income
Adagio Medical's losses deepened to $3.77 per share in 2024 Q4 from a loss of $1.09 per share in 2023 Q4, representing a 247.1% wider loss. Meanwhile, the company's net loss widened to $-57.37 million in 2024 Q4, marking a 565.5% increase from the $-8.62 million loss recorded in 2023 Q4. The EPS performance reflects significant challenges for the company.
Price Action
The stock price of Adagio Medical has edged up 2.52% during the latest trading day, has tumbled 12.23% during the most recent full trading week, and has surged 51.27% month-to-date.
Post-Earnings Price Action Review
The strategy of buying Adagio Medical shares after its revenue drop quarter-over-quarter on the financial report release date and holding for 30 days has yielded mixed results over the past five years. While there were instances of positive returns, these were not consistently robust, and the strategy demonstrated considerable volatility. The backtest revealed a maximum return of 15.23% in 2024, achieved when the revenue drop coincided with a broader market uptrend. Conversely, the strategy experienced a significant loss of -18.15% in 2023 during adverse market conditions. The performance lacked consistency, indicating that the strategy may not be reliable in varying market environments. With a high standard deviation of 10.47%, the strategy’s returns were notably volatile, making it unsuitable for risk-averse investors. Timing proved crucial, as demonstrated by the contrasting outcomes in 2023 and 2024. In conclusion, while some positive returns were noted, the overall inconsistency and volatility render this strategy a risky approach.
CEO Commentary
Adagio Medical's Chief Executive Officer, Todd Usen, expressed that the first quarter of 2025 has been pivotal for the company, highlighting significant achievements such as receiving FDA's Breakthrough Device Designation for the vCLAS™ Cryoablation System. He noted the progress in the FULCRUM-VT clinical trial, with over 50% enrollment, and emphasized the innovative strides in their Ultra-Low Temperature Cryoablation technology. Usen articulated pride in the team's accomplishments and reinforced the commitment to transforming patient treatment for those suffering from ventricular tachycardia, reflecting an optimistic outlook on the company's potential.
Guidance
Adagio Medical anticipates continued momentum in its clinical trial activities and product development, aiming for the completion of patient enrollment in the FULCRUM-VT study in the second half of 2025. The company expects to leverage the FDA's Breakthrough Device Designation for expedited review processes, enhancing its market positioning. Forward-looking statements indicate a focus on advancing the ULTC technology and preparing for potential FDA approval, emphasizing a commitment to meeting market demands and addressing the needs of an underserved patient population.
Additional News
Adagio Medical has made significant strides in its corporate structure and strategic direction recently. The company appointed Deborah Kaster as Chief Business Officer, bringing over 25 years of leadership experience in the medical technology sector. Her appointment is part of a broader corporate prioritization initiative, focusing resources on the FULCRUM-VT clinical trial and product design optimization. Additionally, Adagio Medical announced its participation in the upcoming BofA Securities Health Care Conference, scheduled for May 13, 2025, highlighting its commitment to engaging with industry stakeholders and advancing its market presence. These developments underscore the company's strategic focus on innovation and operational excellence.
Revenue
The total revenue of Adagio MedicalADGM-- increased by 75.6% to $137,000 in 2024 Q4, up from $78,000 in 2023 Q4.
Earnings/Net Income
Adagio Medical's losses deepened to $3.77 per share in 2024 Q4 from a loss of $1.09 per share in 2023 Q4, representing a 247.1% wider loss. Meanwhile, the company's net loss widened to $-57.37 million in 2024 Q4, marking a 565.5% increase from the $-8.62 million loss recorded in 2023 Q4. The EPS performance reflects significant challenges for the company.
Price Action
The stock price of Adagio Medical has edged up 2.52% during the latest trading day, has tumbled 12.23% during the most recent full trading week, and has surged 51.27% month-to-date.
Post-Earnings Price Action Review
The strategy of buying Adagio Medical shares after its revenue drop quarter-over-quarter on the financial report release date and holding for 30 days has yielded mixed results over the past five years. While there were instances of positive returns, these were not consistently robust, and the strategy demonstrated considerable volatility. The backtest revealed a maximum return of 15.23% in 2024, achieved when the revenue drop coincided with a broader market uptrend. Conversely, the strategy experienced a significant loss of -18.15% in 2023 during adverse market conditions. The performance lacked consistency, indicating that the strategy may not be reliable in varying market environments. With a high standard deviation of 10.47%, the strategy’s returns were notably volatile, making it unsuitable for risk-averse investors. Timing proved crucial, as demonstrated by the contrasting outcomes in 2023 and 2024. In conclusion, while some positive returns were noted, the overall inconsistency and volatility render this strategy a risky approach.
CEO Commentary
Adagio Medical's Chief Executive Officer, Todd Usen, expressed that the first quarter of 2025 has been pivotal for the company, highlighting significant achievements such as receiving FDA's Breakthrough Device Designation for the vCLAS™ Cryoablation System. He noted the progress in the FULCRUM-VT clinical trial, with over 50% enrollment, and emphasized the innovative strides in their Ultra-Low Temperature Cryoablation technology. Usen articulated pride in the team's accomplishments and reinforced the commitment to transforming patient treatment for those suffering from ventricular tachycardia, reflecting an optimistic outlook on the company's potential.
Guidance
Adagio Medical anticipates continued momentum in its clinical trial activities and product development, aiming for the completion of patient enrollment in the FULCRUM-VT study in the second half of 2025. The company expects to leverage the FDA's Breakthrough Device Designation for expedited review processes, enhancing its market positioning. Forward-looking statements indicate a focus on advancing the ULTC technology and preparing for potential FDA approval, emphasizing a commitment to meeting market demands and addressing the needs of an underserved patient population.
Additional News
Adagio Medical has made significant strides in its corporate structure and strategic direction recently. The company appointed Deborah Kaster as Chief Business Officer, bringing over 25 years of leadership experience in the medical technology sector. Her appointment is part of a broader corporate prioritization initiative, focusing resources on the FULCRUM-VT clinical trial and product design optimization. Additionally, Adagio Medical announced its participation in the upcoming BofA Securities Health Care Conference, scheduled for May 13, 2025, highlighting its commitment to engaging with industry stakeholders and advancing its market presence. These developments underscore the company's strategic focus on innovation and operational excellence.
Que se dé a conocer la lista de los informes de resultados de las empresas destacadas, después de que cierren las bolsas hoy y antes de que abran las bolsas mañana.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments

No comments yet